<P>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,EN.jsp" target=_blank>The Lyon-based company</A></STRONG> M&#233;rieux D&#233;veloppement, private equity arm of the French group Institut M&#233;rieux has become a reference shareholder in Lavorel Medicare. </STRONG></P> <P align=justify>&nbsp;</P> <P align=justify>This is part of the expansion strategy of Lavorel Medicare, a privately held company providing <STRONG>intensive care services at home or in specialized care units</STRONG>. Its brand<STRONG> Bonitas is a market leader in Germany where it employs more than 3,000 people in 50 agencies</STRONG>. The company wishes to keep on expanding its international presence through selected acquisitions.</P> <P align=justify>&nbsp;</P> <P align=justify>According to Fran&#231;ois Valencony, General Manager of M&#233;rieux D&#233;veloppement, &#8220;<EM>Both companies share the same dedication to high quality standards and innovation for patients</EM>&#8221;. </P> <P align=justify>&nbsp;</P> <P align=justify><STRONG>M&#233;rieux D&#233;veloppement, with</STRONG> <STRONG>2012 consolidated revenues of &#8364;1.8 billion, invests in the healthcare sector on a global basis</STRONG>. The company works alongside entrepreneurs whose products and services can bring genuine advances to the health of patients and consumers worldwide, offering them access to its industry expertise and global network.<BR></P>